Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Medexus Pharmaceuticals Inc (MEDXF)
Medexus Pharmaceuticals Inc (MEDXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MEDXF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8624 +10.92%
on 05/16/23
1.0900 -12.24%
on 05/03/23
-0.0565 (-5.58%)
since 04/26/23
3-Month
0.8624 +10.92%
on 05/16/23
1.3400 -28.61%
on 03/02/23
-0.3294 (-25.61%)
since 02/24/23
52-Week
0.5850 +63.52%
on 10/03/22
2.5280 -62.16%
on 08/10/22
-0.7034 (-42.37%)
since 05/26/22

Most Recent Stories

More News
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Convertible Debentures

NCIB will commence on May 15, 2023 and is expected to continue through the debentures' October 2023 maturity dateNCIB purchases will deleverage Medexus's balance sheet and lead to lower overall debt levels...

MDP.TO : 1.30 (+4.84%)
MEDXF : 0.9566 (+2.67%)
Medexus Demonstrates Cost-Effectiveness of Gleolan-Guided Surgery for High-Grade Glioma

ISPOR 2023 Presentation Shows 33% Lowered Costs with Gleolan Compared to Conventional White Light SurgeryToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 9, 2023) - Medexus Pharmaceuticals...

MDP.TO : 1.30 (+4.84%)
MEDXF : 0.9566 (+2.67%)
Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022

Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA, regulatory...

MDP.TO : 1.30 (+4.84%)
MEDXF : 0.9566 (+2.67%)
Medexus Schedules First Quarter 2023 Conference Call

TORONTO and CHICAGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at...

MDP.TO : 1.30 (+4.84%)
MEDXF : 0.9566 (+2.67%)
Treosulfan NDA Resubmitted to FDA

FDA decision expected within six months of acceptancePivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints TORONTO...

MDP.TO : 1.30 (+4.84%)
MEDXF : 0.9566 (+2.67%)
Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)

Management to host conference call at 8:00 AM Eastern Time on Thursday, June 23, 2022...

MDP.TO : 1.30 (+4.84%)
MEDXF : 0.9566 (+2.67%)
Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call

TORONTO and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at...

MDP.TO : 1.30 (+4.84%)
MEDXF : 0.9566 (+2.67%)
Treosulfan Pivotal Study Results Published

Study’s primary endpoint and key secondary endpoints were met Study found event-free survival and overall survival superior after treosulfan compared to...

MDP.TO : 1.30 (+4.84%)
MEDXF : 0.9566 (+2.67%)
Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA

TORONTO and CHICAGO, May 24, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic...

MDP.TO : 1.30 (+4.84%)
MEDXF : 0.9566 (+2.67%)
Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA

Additional data collection and analysis reconfirms confidence in New Drug Application for TreosulfanNDA resubmission date consistent with previously...

MDP.TO : 1.30 (+4.84%)
MEDXF : 0.9566 (+2.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.9566
2nd Resistance Point 0.9566
1st Resistance Point 0.9566
Last Price 0.9566
1st Support Level 0.9566
2nd Support Level 0.9566
3rd Support Level 0.9566

See More

52-Week High 2.5280
Fibonacci 61.8% 1.7858
Fibonacci 50% 1.5565
Fibonacci 38.2% 1.3272
Last Price 0.9566
52-Week Low 0.5850

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar